Professor Carolyn A. Young has been a Consultant Neurologist at the Walton Centre since 1992 and a professor of neurology at the University of Liverpool since 2006. Since appointment as a consultant in 1992, the multiple sclerosis (MS) service that she founded has expanded into a multi-disciplinary team offering a comprehensive range of services. She also set up the Walton Motor Neurone Disease (MND) service in 1999. She has been the principal investigator for over 120 trials and has written over 180 papers. Professor Young participated in the NICE assessment process for beta interferon, glatiramer acetate, natalizumab, fingolimod, and riluzole. She was a member of NICE Technology Assessment Committee D for several years. Currently, her main research focus involves the Trajectories of Outcome in Neurological Conditions (TONiC) study. She has considerable experience disseminating evidence-based medicine guidance and is an international editor for two Cochrane Editorial Boards: Multiple Sclerosis and Rare Diseases of the Central Nervous System, and Neuromuscular Disease.
Professor Carolyn A. Young has been a Consultant Neurologist at the Walton Centre since 1992 and a professor of neurology at the University of Liverpool since 2006. Since appointment as a consultant in 1992, the multiple sclerosis (MS) service that she founded has expanded into a multi-disciplinary team offering a comprehensive range of services. She also set up the Walton Motor Neurone Disease (MND) service in 1999. She has been the principal investigator for over 120 trials and has written over 180 papers. Professor Young participated in the NICE assessment process for beta interferon, glatiramer acetate, natalizumab, fingolimod, and riluzole. She was a member of NICE Technology Assessment Committee D for several years. Currently, her main research focus involves the Trajectories of Outcome in Neurological Conditions (TONiC) study. She has considerable experience disseminating evidence-based medicine guidance and is an international editor for two Cochrane Editorial Boards: Multiple Sclerosis and Rare Diseases of the Central Nervous System, and Neuromuscular Disease.